Between the dates 23-26 September 2012, the city of Istanbul, where two continents meet, will host the 15th European Congress on Biotechnology, with the European Federation of Biotechnology and Biotechnology Association of Turkey.
This event will be organized together with:
ESBES – 9th European Symposium on Biochemical Engineering Service
ISPPP – 32nd International Symposium on the Separation of Proteins, Peptides and Polynucleotides
17th Turkish National Biotechnology Congress
ACIB-Industrial Biotechnology in Austria Satellite Symposium “Biotechnology for Industrial Production” .
Congress sessions are expected to include Scale up of Bioprocesses, Biobased Chemicals & Materials, Bioenergy / Biofuels, Biorefineries, Personalised and Stratified Medicine, Next Gen Sequencing & Human Genome & Epigenecits, Cancer Genomics and Interventions, Stem Cells, Affinity Proteomics, Nanobiotechnology, Synthetic biology and Tissue Engineering.
Important speakers such as George Whitesides, Ruedi Aebersold, Werner Arber,Yang Huanming are expected to share their academic and professional life knowledge in the biotechnology world. “Early Bird” registration has been extended to July 16th! You may register via http://www.ecb15.org
You may also follow news on social media accounts http://www.facebook.com/EuroBiotechnology and http://www.twitter.com/EuroBiotech
RESEARCH TRIANGLE PARK, N.C. – Liquidia’s technology and drug development deal with GlaxoSmithKline (NYSE: GSK) has the potential to both make the world healthier and a lot of people richer. But Dr. Joseph DeSimone, the company’s founder and pioneer into the development of the nanotechnology that could revolutionize medicine, was most excited about the “team” that is commercializing his work while he continues to teach and pursue new inventions.
“As a founder, consultant and member of the Board of Directors I can’t express to you enough how excited and proud I am of the PRINT technology team at Liquidia, UNC and NCSU, as well as the business development and leadership team at Liquidia,” the distinguished professor told The Skinny shortly after the GSK deal was announced on June 20.
PRINT refers to Liquidia’s proprietary technology that someday could enable drugs to be enhanced and made much more effective in their design as well as delivery. Rest
If you break a bone, you know you’ll end up in a cast for weeks. But what if the time it took to heal a break could be cut in half? Or cut to just a tenth of the time it takes now?
Qian Wang, a chemistry professor at the University of South Carolina, has made tantalizing progress toward that goal.
Qian Wang and co-workers recently reported in Molecular Pharmaceutics that surfaces coated with bio-nanoparticles could greatly accelerate the early phases of bone growth. (Photo/Provided)
Wang, Andrew Lee and co-workers recently reported in Molecular Pharmaceutics that surfaces coated with bio-nanoparticles could greatly accelerate the early phases of bone growth. Their coatings, based in part on genetically modified tobacco mosaic virus, reduced the amount of time it took to convert stem cells into bone nodules — from two weeks to just two days.
The key to hastening bone healing or growth is to coax a natural process to pick up the pace. Rest